NCE-1 Intelligence & Market Opportunity

Sohonos

Palovarotene

Antiossification

Oral Capsules

Sohonos is a daily oral capsule for patients (8 + for females, 10 + for males) with fibrodysplasia ossificans progressiva (FOP), a condition causing abnormal bone growth. It slows new bone formation by activating retinoic acid receptors.

Approval Date

16-Aug-23

NCE-1 Date

16-Aug-27

NCE Date

16-Aug-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

-0.0446

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Palovarotene

Innovator

IPSEN BIOPHARMACEUTICALS INC

Dosage Form

Oral Capsules

Strength

1 mg, 1.5 mg, 2.5 mg, 5 mg and 10 mg

Therapeutic Category

Antiossification

Usage

To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.